EUVIMEDEUVIMED entdecken
Crossref

EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS

Ifechukwu B. Nwogu, Noemi Kreif, Hiba Khan, Ruth Etzioni, Josh J. Carlson

Value in Health · 2026-06 · 29 (6) · S72

DOI: 10.1016/j.jval.2026.03.342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Ifechukwu B. Nwogu und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Nwogu, I. B., Kreif, N., Khan, H., Etzioni, R., & Carlson, J. J. (2026). EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS. Value in Health, 29(6), S72. https://doi.org/10.1016/j.jval.2026.03.342

Vancouver

Nwogu IB, Kreif N, Khan H, Etzioni R, Carlson JJ. EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS. Value in Health. 2026;29(6):S72. doi:10.1016/j.jval.2026.03.342

BibTeX
@article{Nwogu2026,
  author = {Nwogu, Ifechukwu B. and Kreif, Noemi and Khan, Hiba and Etzioni, Ruth and Carlson, Josh J.},
  title = {EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S72},
  doi = {10.1016/j.jval.2026.03.342}
}
Kostenlos starten →